SCHEMBL5223601

SCHEMBL5223601

CC(C)(C)c1ccc(C(=O)Nc2cc(NS(C)(=O)=O)ccc2C(=O)Nc2cccc(O)c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 14/20 0.58
PPARG P37231 7/20 0.56
PPARD Q03181 2/20 0.54
GPBAR1 Q8TDU6 1/20 0.54
PPARA Q07869 5/20 0.53
HPGD P15428 1/20 0.53
KCNK9 Q9NPC2 1/20 0.51
UQCRB P14927 1/20 0.51
TP53 P04637 1/20 0.51
THRB P10828 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
MEN1 O00255 1/20 0.51
ALDH1A1 P00352 1/20 0.51
MAPK1 P28482 1/20 0.51
HTT P42858 1/20 0.51
RAB9A P51151 1/20 0.51
KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5226932 0.93 NR1H4 (0.57) NR1H4PPARGPPARDPPARAHPGD
SCHEMBL5226509 0.84 NR1H4 (0.57) NR1H4PPARGPPARDGPBAR1PPARA
SCHEMBL5224325 0.84 NR1H4 (0.80) NR1H4PPARGPPARDPPARAKCNK9
SCHEMBL5223117 0.82 F10 (0.64) NR1H4PPARGPPARDGPBAR1PPARA
SCHEMBL5223109 0.81 RAB9A (0.70) NR1H4SMN1; SMN2MEN1ALDH1A1MAPK1
SCHEMBL6169059 0.81 ESR1 (0.56) NR1H4PPARGPPARDGPBAR1PPARA
SCHEMBL7292693 0.81 KCNK9 (0.75) NR1H4KCNK9TP53THRBSMN1; SMN2
SCHEMBL6168129 0.80 MAP4K4 (0.54) NR1H4HPGDSMN1; SMN2MEN1ALDH1A1
SCHEMBL5226947 0.77 NR1H4 (0.55) NR1H4PPARGPPARDPPARAKCNK9
SCHEMBL6169846 0.77 ESR1 (0.55) NR1H4PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1014962-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2007-06-27 EP disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 NR1H4 2304/4885PPARG 2764/4885PPARD 3501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.